When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Apr 2025
Last updated: 02 Aug 2023

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • infection with other parasites

Other diagnostic factors

  • abdominal pain
  • altered bowel habit
  • weight loss
  • fever (hyperinfection)
  • signs of sepsis (hyperinfection)
  • chronic cough
  • wheezing
  • pruritus or dermatitis
  • larva currens
  • urticaria
  • cutaneous larva migrans
  • apparent drug reaction rash (hyperinfection)
  • other skin complaints
  • symptoms and signs of inflammatory bowel disease

Risk factors

  • soil exposure in or migrants from an endemic area of the world
  • international travellers
  • corticosteroids (risk of hyperinfection)
  • human T-cell lymphotropic virus type-1 (HTLV-1) infection (risk of hyperinfection)
  • impaired immunity
  • solid-organ transplant recipient

Diagnostic investigations

1st investigations to order

  • stool ova and parasites (O&P) examination
  • FBC with differential
  • therapeutic trial with ivermectin (in specific situations)

Investigations to consider

  • sputum O&P examination
  • clinical sample (non-stool or sputum) O&P examination
  • strongyloides IgG serology
  • tissue biopsy

Emerging tests

  • polymerase chain reaction (PCR)

Treatment algorithm

Contributors

Authors

David R. Boulware, MD, MPH, CTropMed
David R. Boulware

Professor of Medicine

Department of Medicine

University of Minnesota

Minneapolis

MN

Disclosures

DRB is an author of a number of references cited in this topic.

Peer reviewers

Elizabeth Barnett, MD

Professor

Department of Pediatrics

Boston Medical Center

Boston University

Boston

MA

Disclosures

EB declares that she is on a speaker's bureau for Merck. She is an author of a reference cited in this topic.

Linda Nield, MD, FAAP

Professor of Pediatrics

West Virginia University School of Medicine

Morgantown

WV

Disclosures

LN is an author of a reference cited in this topic.

Geoff Gill, MA, MSc, MD, FRCP, DTMH

Professor of International Medicine and Honorary Consultant Physician

Liverpool School of Tropical Medicine

Liverpool

UK

Disclosures

GG declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

World Gastroenterology Organisation. WGO practice guideline: management of strongyloidiasis. February 2018 [internet publication].Full text

Loutfy MR, Wilson M, Keystone JS, et al. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg. 2002 Jun;66(6):749-52. Abstract

Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18;(1):CD007745.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer